Apic Bio receives FDA Fast Track Designation for APB-102 for treatment of patients with SOD1 ALS
The US FDA has granted Fast Track designation to APB-102, Apic Bio’s lead gene therapy candidate designed to treat SOD1 amyotrophic lateral sclerosis (ALS). Apic said they plan to commence a Phase 1/2 clinical trial in early 2022.